EMA Recommends Granting a Marketing Authorisation for Accordpharma Enzalutamide By Ogkologos - December 5, 2025 310 0 Facebook Twitter Google+ Pinterest WhatsApp It is a generic and hybrid of Xtandi, which has been authorised in the EU since 2013 Source RELATED ARTICLESMORE FROM AUTHOR Anito-cel, a d-Domain BCMA CAR T-Cell, Induces Rapid, Deep, and Durable Responses in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma EMA Recommends Granting a Marketing Authorisation for Relacorilant Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... MOST POPULAR A Combination of Tucatinib and Trastuzumab Demonstrates Activity and Favourable Tolerability... October 9, 2023 Trametinib Is a New Treatment Option for Rare Form of Ovarian... March 10, 2022 Zanubrutinib’s Approval Improves Targeted Treatment for CLL January 27, 2023 Trial Examines Value of Lymph Node Surgery in Advanced Ovarian Cancer March 27, 2019 Load more HOT NEWS Take with Food: Study Tests Lowering Dose of Prostate Cancer Drug World No Tobacco Day 2024: European Societies call for an EU... New Treatment Combinations Slow Progression of Prostate Cancer and Stomach and... Efficacy of Afamitresgene Autoleucel for HLA-A*02-positive and MAGE-A4-positive Synovial Sarcoma Following...
